HighTower Advisors
RIGL icon

HighTower Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

HighTower Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6,400
Closed -$38.4K – 3868
2024
Q1 		$38.4K Buy
+6,400
New +$86.3K ﹤0.01% 3291
2023
Q2 		– Sell
-1,800
Closed -$8.1K – 3639
2023
Q1 		$8.1K Buy
+1,800
New +$28.6K ﹤0.01% 3205
2019
Q1 		– Sell
-200
Closed -$2K – 2400
2018
Q4 		$2K Hold
200
– – ﹤0.01% 2177
2018
Q3 		$2K Buy
+200
New +$6K ﹤0.01% 2252

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HighTower Advisors's RIGL Position: Q1 2026 in Review

HighTower Advisors sold out of Rigel Pharmaceuticals (RIGL) in Q1 2026, closing a stake of 11,088 shares — an estimated $475K sold.

HighTower Advisors first reported a position in RIGL in Q2 2013 and held it in 33 quarters. The position peaked at $475K in Q4 2025. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • HighTower Advisors reported no remaining Rigel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • HighTower Advisors sold 11,088 Rigel Pharmaceuticals shares in Q1 2026, an estimated $475K.
  • HighTower Advisors first reported a position in Rigel Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • HighTower Advisors's Rigel Pharmaceuticals position peaked at $475K in Q4 2025.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.